NASDAQ:LIVN - LivaNova Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $98.50
  • Forecasted Upside: 52.22 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.17 (1.84%)

This chart shows the closing price for LIVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LivaNova Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LIVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LIVN

Analyst Price Target is $98.50
▲ +52.22% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for LivaNova in the last 3 months. The average price target is $98.50, with a high forecast of $108.00 and a low forecast of $88.00. The average price target represents a 52.22% upside from the last price of $64.71.

This chart shows the closing price for LIVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in LivaNova. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2022Needham & Company LLCLower Price TargetBuy$106.00 ➝ $88.00Low
5/5/2022Piper SandlerLower Price Target$104.00 ➝ $99.00High
4/5/2022Wolfe ResearchInitiated CoverageOutperform$95.00Medium
2/24/2022UBS GroupUpgradeNeutral ➝ Buy$96.00High
2/24/2022Needham & Company LLCLower Price TargetBuy$120.00 ➝ $106.00High
12/3/2021Needham & Company LLCReiterated RatingBuy$119.00Medium
12/3/2021The Goldman Sachs GroupInitiated CoverageBuy$108.00High
11/3/2021Piper SandlerBoost Price TargetIn-Line ➝ Overweight$100.00 ➝ $105.00Medium
11/3/2021Needham & Company LLCBoost Price TargetBuy$117.00 ➝ $120.00High
8/20/2021Needham & Company LLCBoost Price TargetBuy$104.00 ➝ $117.00High
8/17/2021Robert W. BairdBoost Price TargetOutperform$100.00 ➝ $105.00Medium
7/20/2021Needham & Company LLCUpgradeHold ➝ Buy$93.00High
6/7/2021Needham & Company LLCReiterated RatingHoldLow
6/1/2021Piper SandlerLower Price TargetOverweight$99.00 ➝ $98.00High
4/29/2021Robert W. BairdBoost Price TargetOutperform$85.00 ➝ $100.00Low
4/28/2021Piper SandlerBoost Price Target$92.00 ➝ $99.00Low
4/13/2021Piper SandlerBoost Price TargetOverweight$81.00 ➝ $92.00Low
3/9/2021Berenberg BankReiterated RatingBuy ➝ Hold$84.00Medium
3/4/2021Needham & Company LLCReiterated RatingHoldLow
3/3/2021Berenberg BankDowngradeBuy ➝ Hold$84.00High
2/24/2021Piper SandlerBoost Price TargetOverweight$73.00 ➝ $81.00High
1/12/2021Piper SandlerBoost Price TargetOverweight$70.00 ➝ $73.00Medium
1/5/2021Needham & Company LLCDowngradeBuy ➝ HoldN/A
12/15/2020Piper SandlerBoost Price TargetOverweight$63.00 ➝ $70.00High
10/29/2020Piper SandlerBoost Price TargetOverweight$60.00 ➝ $63.00High
10/21/2020Robert W. BairdBoost Price TargetOutperform$55.00 ➝ $65.00Medium
9/1/2020Robert W. BairdInitiated CoverageOutperform$55.00Low
7/29/2020Piper SandlerLower Price TargetPositive ➝ Overweight$65.00 ➝ $60.00Low
7/29/2020Needham & Company LLCLower Price TargetBuy$76.00 ➝ $68.00High
6/26/2020Needham & Company LLCLower Price TargetBuy$84.00 ➝ $76.00High
4/30/2020UBS GroupLower Price TargetNeutral$70.00 ➝ $57.00Medium
4/29/2020Piper SandlerLower Price TargetOverweight$80.00 ➝ $65.00Low
3/24/2020Stifel NicolausLower Price TargetBuy$80.00 ➝ $40.00High
2/27/2020Berenberg BankReiterated RatingBuy$114.00High
11/25/2019Stifel NicolausBoost Price TargetBuy$80.00 ➝ $90.00High
11/20/2019Needham & Company LLCReiterated RatingBuy$88.00Low
10/30/2019Needham & Company LLCLower Price TargetBuy$91.00 ➝ $88.00Medium
9/9/2019Berenberg BankReiterated RatingBuy$114.00Low
9/6/2019Piper Jaffray CompaniesSet Price TargetBuy$90.00Low
9/6/2019Needham & Company LLCReiterated RatingBuy$91.00Medium
7/31/2019Needham & Company LLCSet Price TargetBuy$91.00Medium
7/31/2019Piper Jaffray CompaniesReiterated RatingBuyN/A
7/31/2019BTIG ResearchReiterated RatingHoldN/A
5/28/2019Needham & Company LLCReiterated RatingBuy$87.00Low
5/15/2019Needham & Company LLCReiterated RatingBuy$87.00Low
5/2/2019BTIG ResearchReiterated RatingHoldHigh
5/1/2019Piper Jaffray CompaniesLower Price TargetOverweight ➝ In-Line$120.00 ➝ $90.00High
4/9/2019Needham & Company LLCReiterated RatingBuy$100.00Low
4/5/2019Stifel NicolausReiterated RatingBuy$100.00Medium
4/2/2019UBS GroupBoost Price TargetNeutral$100.00 ➝ $105.00Low
3/5/2019BTIG ResearchReiterated RatingHoldLow
2/27/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$135.00 ➝ $120.00High
11/27/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$105.00High
11/21/2018BTIG ResearchReiterated RatingHoldLow
11/1/2018BTIG ResearchReiterated RatingHoldMedium
10/2/2018Jefferies Financial GroupBoost Price TargetBuy$150.00Low
9/17/2018Stifel NicolausBoost Price TargetBuy$135.00 ➝ $140.00Low
8/2/2018Stifel NicolausReiterated RatingBuy$135.00Medium
8/1/2018Needham & Company LLCReiterated RatingBuy$128.00 ➝ $135.00High
7/24/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$115.00 ➝ $130.00High
7/18/2018Needham & Company LLCReiterated RatingBuy$128.00Low
6/8/2018Stifel NicolausInitiated CoverageBuy$115.00Medium
5/31/2018Needham & Company LLCReiterated RatingBuy$102.00 ➝ $106.00High
5/3/2018BTIG ResearchReiterated RatingHoldLow
2/28/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$97.00 ➝ $104.00Low
12/5/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$93.00 ➝ $97.00Low
11/21/2017Needham & Company LLCBoost Price TargetBuy$93.00N/A
11/7/2017BTIG ResearchReiterated RatingHoldN/A
11/3/2017Piper Jaffray CompaniesReiterated RatingBuy$85.00N/A
11/3/2017Jefferies Financial GroupBoost Price TargetBuy$80.00 ➝ $91.00N/A
11/3/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$83.00 ➝ $89.00N/A
9/15/2017Jefferies Financial GroupBoost Price TargetBuy$76.00 ➝ $80.00Low
9/15/2017Needham & Company LLCUpgradeHold ➝ Buy$83.00Low
9/14/2017Needham & Company LLCUpgradeHold ➝ Buy$83.00High
9/12/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$75.00Low
9/8/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$76.00High
8/23/2017Needham & Company LLCInitiated CoverageHold ➝ HoldLow
8/15/2017WBB SecuritiesDowngradeHold ➝ Sell$50.00Low
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
LivaNova logo
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $64.71
Low: $63.42
High: $64.81

50 Day Range

MA: $62.65
Low: $57.25
High: $70.05

52 Week Range

Now: $64.71
Low: $56.13
High: $93.89


169,985 shs

Average Volume

344,724 shs

Market Capitalization

$3.46 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of LivaNova?

The following Wall Street analysts have issued reports on LivaNova in the last year: Needham & Company LLC, Piper Sandler, Robert W. Baird,, The Goldman Sachs Group, Inc., UBS Group AG, and Wolfe Research.
View the latest analyst ratings for LIVN.

What is the current price target for LivaNova?

6 Wall Street analysts have set twelve-month price targets for LivaNova in the last year. Their average twelve-month price target is $98.50, suggesting a possible upside of 52.2%. The Goldman Sachs Group, Inc. has the highest price target set, predicting LIVN will reach $108.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $88.00 for LivaNova in the next year.
View the latest price targets for LIVN.

What is the current consensus analyst rating for LivaNova?

LivaNova currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LIVN will outperform the market and that investors should add to their positions of LivaNova.
View the latest ratings for LIVN.

What other companies compete with LivaNova?

How do I contact LivaNova's investor relations team?

LivaNova's physical mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company's listed phone number is 442033250660 and its investor relations email address is [email protected] The official website for LivaNova is Learn More about contacing LivaNova investor relations.